GSK begins trials of swine flu vaccine in Germany
British pharmaceuticals group GlaxoSmithKline said Friday it had begun clinical trials in Germany of a vaccine to combat the swine flu pandemic, with results expected from next month.
"The first clinical trial, being conducted in Germany, will assess the use of the vaccine in healthy adults. Initial data is expected to be available for sharing with regulatory authorities in September," GSK said in a statement.
GSK added further trials of the vaccine, called Pandemic (H1N1) 2009, would begin over coming weeks across Europe, Canada and the United States to cover infants, children, adults and the elderly.
GSK is among a select few leading pharmaceutical companies that are creating vaccines against the A(H1N1) virus for millions of people to take ahead of the northern hemisphere winter so that they avoid contracting the illness.